Association between Karnofsky performance status and outcomes in cancer patients on home parenteral nutrition

Background and aim: The selection of appropriate criteria is essential to accurately identify cancer pa-tients eligible for home parenteral nutrition (HPN). In this study, the association between Karnofsky Performance Status (KPS) Scale scores and outcomes in cancer patients on HPN was evaluated.Methods: Retrospective-observational-longitudinal-analytical study of a database of adult cancer pa-tients on HPN. The variables analyzed were sex, age, cancer diagnosis, cancer location (digestive tract and genitourinary), nutritional status, including initial weight (IW), at the start of HPN), usual weight (LRA/) and IW/UW ratio, and body mass index (BMI) at the start of HPN. Performance status was assessed with the KPS scale. Type of catheter used, number of days on HPN and clinical progression of cancer patients were also studied.Results: Data of 41 cancer patients (60.8% female) were evaluated. Mean age at the start of HPN was 60.45 years. Cancer location was digestive tract (n = 36; 87.8%); gynecologic (n = 4; 9.7%), urinary tract (n = 1; 2.4%). Median IW was 55 kg (45; 64) and BMI was 20 (17.58; 22.84). The IW/UW ratio was -15 kg (-20;-10). The catheters used were peripherally inserted central catheter (n = 30; 73.2%), tunneled (n = 9; 22%) and port (n = 2; 4.8%). The median duration of HPN was 72 days (30; 159). The KPS results showed that 16 cancer patients (39%) had KPS scores <50,17 (41.5%) requiring HPN were discharged and 24 (58.5%) died. The association between disease progression and KPS scores c50 was significant (p = 0.025; OR (95% CI): 5.28 (1.07; 36.18).Conclusion: The KPS scale is a reliable tool to identify cancer patients eligible for HPN. Cancer patients with <50 scores had a five-fold increased risk of death than patients with >50 scores.C 2023 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.